Veliparib Medicine 09 January 2018 Extended indication Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage III or IV high-grade - first-line with carboplatin and paclitaxel. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Veliparib Domain Oncology and Hematology Reason of inclusion Main indication Ovarian cancer Extended indication Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage III or IV high-grade - first-line with carboplatin and paclitaxel. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Abbvie Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume < 66 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR Additional remarks Hoog stadium (FIGO III en IV) ovariumcarcinoom, hooggradig sereus, behandeld met o.a. chemotherapie in de eerste lijn. Selectie uit NKR: 1316 patiënten over in 2014 en 2015. Schatting: 10% BRCA1 in de populatie (gebaseerd op de literatuur en praktijk). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks